Healthtech Startup Mestastop Solutions Partners Vipragen Biosciences to Enhance Oncology Services

The agreement outlined terms for mutual collaboration in novel drug discovery, drug repurposing, and profiling anti-cancer leads for their anti-metastatic effects. The central goal was to bolster each other's offerings for comprehensive cancer and metastasis solutions.

Bengaluru-based cancer drug discovery startup, Mestastop Solutions, has inked a Memorandum of Understanding (MoU) with Mysore's contract research organisation (CRO), Vipragen Biosciences. 

The collaboration aimed to elevate Vipragen's global oncology services using Mestastop's proprietary platforms.

Commenting on the same, Dr S Chandrashekaran, chairman and managing director of Vipragen, said, "This partnership is exceptionally distinctive and strategic, leveraging Vipragen’s vivarium and harnessing Mestastop’s proprietary platforms for metastasis drug discovery and early predictive diagnostics."

The agreement outlined terms for mutual collaboration in novel drug discovery, drug repurposing, and profiling anti-cancer leads for their anti-metastatic effects. The central goal was to bolster each other's offerings for comprehensive cancer and metastasis solutions, with each party retaining ownership of their intellectual property.

Commenting on the development, Dr Arnab Roy Chowdhury, founder and director of Mestastop, said, "To partner with an established CRO like Vipragen allows us to empower Biotech and Pharma seeking novel cancer-fighting solutions."

Founded in 2018, Mestastop Solutions focuses on cancer metastasis through a combination of wet-lab biology and predictive analytics. The collaboration aimed to discover new drugs and enhance patient treatments.

In October this year, Mestastop Solutions raised INR 4.5 Cr in a Pre-Series A funding round. This funding, led by 92 angel investors with support from Malpani Ventures, will be directed towards generating proof of concept data for small molecules targeting identified cancer-related targets.

Simultaneously, the American Oncology Institute at Nangia Specialty Hospital in Nagpur inaugurated a dedicated Lung Cancer Unit, enhancing diagnostic and management efforts for lung cancer. The multidisciplinary team ensures a personalised treatment approach for each patient.

In 2021, the global oncology market was valued at $286.04 billion, with projections estimating it to reach $536.01 billion by 2029, representing a compound annual growth rate (CAGR) of 8.2% from 2021 to 2030.

Further, in another development, Venus Remedies Ltd, a Haryana-based pharmaceutical company specialising in oncology treatments, obtained marketing authorisation in Serbia for two vital chemotherapy drugs, gemcitabine and docetaxel, recognised for their efficacy in treating various cancer types.